Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

Trial Profile

Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs Ensartinib (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Acronyms eXalt2; Xalt2
  • Sponsors Xcovery Holdings
  • Most Recent Events

    • 07 Dec 2016 Results of plasma genotyping and response in patients with ALK+ non-small cell lung cancer (n=83) presented at the 17th World Conference on Lung Cancer
    • 01 Nov 2016 Results (n=83) published in the Journal of Thoracic Oncology
    • 11 Oct 2016 Results (n=71, data cut off April 2015) assessing correlation with plasma and tissue genotyping and response to therapy presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top